Abonnement à la biblothèque: Guest
Critical Reviews™ in Oncogenesis

Publication de 4  numéros par an

ISSN Imprimer: 0893-9675

ISSN En ligne: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

Intrinsic and Acquired Resistance to HER2-Targeted Therapies in HER2 Gene-Amplified Breast Cancer: Mechanisms and Clinical Implications

Volume 17, Numéro 1, 2012, pp. 1-16
DOI: 10.1615/CritRevOncog.v17.i1.20
Get accessGet access

RÉSUMÉ

Approximately 25% of human breast cancers overexpress the HER2 (ErbB2) proto-oncogene, which confers a more aggressive tumor phenotype and associates with a poor prognosis in patients with this disease. Two approved therapies targeting HER2, the monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib, are clinically active against this type of breast cancer. However, a significant fraction of patients with HER2+ breast cancer treated with these agents eventually relapse or develop progressive disease. This suggests that tumors acquire or possess intrinsic mechanisms of resistance that allow escape from HER2 inhibition. This review focuses on mechanisms of intrinsic and/or acquired resistance to HER2-targeted therapies that have been identified in preclinical and clinical studies. These mechanisms involve alterations to HER2 itself, coexpression or acquisition of bypass signaling through other receptor or intracellular signaling pathways, defects in mechanisms of cell cycle regulation or apoptosis, and host factors that may modulate drug response. Emerging clinical evidence already suggests that combinations of therapies targeting HER2 as well as these resistance pathways will be effective in overcoming or preventing resistance.

CITÉ PAR
  1. Orzáez M, Guevara T, Sancho M, Pérez-Payá E, Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment, Cell Death & Disease, 3, 10, 2012. Crossref

  2. Roskoski Robert, The ErbB/HER family of protein-tyrosine kinases and cancer, Pharmacological Research, 79, 2014. Crossref

  3. Montemurro Filippo, Scaltriti Maurizio, Biomarkers of drugs targeting HER-family signalling in cancer, The Journal of Pathology, 232, 2, 2014. Crossref

  4. Bian Li, Wang Tao, Zhang Shaohua, Jiang Zefei, Trastuzumab plus capecitabine vs. lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer, Tumor Biology, 34, 5, 2013. Crossref

  5. Montemurro F., Di Cosimo S., Arpino G., Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications, Annals of Oncology, 24, 11, 2013. Crossref

  6. Dharmawardhane Suranganie, Hernandez Eliud, Vlaar Cornelis, Development of EHop-016, in Inhibitors of the Ras Superfamily G-proteins, Part A, 33, 2013. Crossref

  7. De Luca Antonella, D'Alessio Amelia, Gallo Marianna, Maiello Monica, Bode Ann, Normanno Nicola, Src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib, Cell Cycle, 13, 1, 2014. Crossref

  8. Hur Ho, Lee Ji-Yeon, Yun Hyo Jung, Park Byeong Woo, Kim Myoung Hee, Analysis of HOX Gene Expression Patterns in Human Breast Cancer, Molecular Biotechnology, 56, 1, 2014. Crossref

  9. Kerdivel Gwenneg, Flouriot Gilles, Pakdel Farzad, Modulation of Estrogen Receptor Alpha Activity and Expression During Breast Cancer Progression, in Hormones and Breast Cancer, 93, 2013. Crossref

  10. Ali Siraj M., Alpaugh R. Kathy, Buell Jamie K., Stephens Philip J., Yu Jian Qin (Michael), Wu Hong, Hiemstra Christine N., Miller Vincent A., Lipson Doron, Palmer Gary A., Ross Jeffrey S., Cristofanilli Massimo, Antitumor Response of an ERBB2 Amplified Inflammatory Breast Carcinoma With EGFR Mutation to the EGFR-TKI Erlotinib, Clinical Breast Cancer, 14, 1, 2014. Crossref

  11. Formisano Luigi, Nappi Lucia, Rosa Roberta, Marciano Roberta, D’Amato Claudia, D’Amato Valentina, Damiano Vincenzo, Raimondo Lucia, Iommelli Francesca, Scorziello Antonella, Troncone Giancarlo, Veneziani Bianca Maria, Parsons Sarah J, De Placido Sabino, Bianco Roberto, Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models, Breast Cancer Research, 16, 3, 2014. Crossref

  12. Krishnan Navasona, Koveal Dorothy, Miller Daniel H, Xue Bin, Akshinthala Sai Dipikaa, Kragelj Jaka, Jensen Malene Ringkjøbing, Gauss Carla-Maria, Page Rebecca, Blackledge Martin, Muthuswamy Senthil K, Peti Wolfgang, Tonks Nicholas K, Targeting the disordered C terminus of PTP1B with an allosteric inhibitor, Nature Chemical Biology, 10, 7, 2014. Crossref

  13. Grabinski Nicole, Möllmann Katharina, Milde-Langosch Karin, Müller Volkmar, Schumacher Udo, Brandt Burkhard, Pantel Klaus, Jücker Manfred, AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2+ breast tumor cells from Balb-neuT mice, Cellular Signalling, 26, 5, 2014. Crossref

  14. Alba E, Albanell J, de la Haba J, Barnadas A, Calvo L, Sánchez-Rovira P, Ramos M, Rojo F, Burgués O, Carrasco E, Caballero R, Porras I, Tibau A, Cámara M C, Lluch A, Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial, British Journal of Cancer, 110, 5, 2014. Crossref

  15. Jachimowicz Ron D., Borchmann Sven, Rothe Achim, Multi-Specific Antibodies for Cancer Immunotherapy, BioDrugs, 28, 4, 2014. Crossref

  16. Yang Yanan, Ahn Young-Ho, Chen Yulong, Tan Xiaochao, Guo Lixia, Gibbons Don L., Ungewiss Christin, Peng David H., Liu Xin, Lin Steven H., Thilaganathan Nishan, Wistuba Ignacio I., Rodriguez-Canales Jaime, McLendon Georgia, Creighton Chad J., Kurie Jonathan M., ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism, Journal of Clinical Investigation, 124, 6, 2014. Crossref

  17. Grabinski Nicole, Ewald Florian, Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells, Investigational New Drugs, 32, 6, 2014. Crossref

  18. Lavaud Pernelle, Andre Fabrice, Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials, BMC Medicine, 12, 1, 2014. Crossref

  19. Estévez Laura G, Suarez-Gauthier Ana, García Elena, Miró Cristina, Calvo Isabel, Fernández-Abad María, Herrero Mercedes, Marcos Manuel, Márquez Cristina, Lopez Ríos Fernando, Perea Sofía, Hidalgo Manuel, Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ, Breast Cancer Research, 16, 4, 2014. Crossref

  20. Yeh Elizabeth S., Abt Melissa A., Hill Elizabeth G., Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors, Breast Cancer Research and Treatment, 149, 1, 2015. Crossref

  21. Carta Alessia, Chetcuti Rachel, Ayers Duncan, An Introspective Update on the Influence of miRNAs in Breast Carcinoma and Neuroblastoma Chemoresistance, Genetics Research International, 2014, 2014. Crossref

  22. Asić Ksenija, Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies, Critical Reviews in Oncology/Hematology, 97, 2016. Crossref

  23. Janiszewska Michalina, Liu Lin, Almendro Vanessa, Kuang Yanan, Paweletz Cloud, Sakr Rita A, Weigelt Britta, Hanker Ariella B, Chandarlapaty Sarat, King Tari A, Reis-Filho Jorge S, Arteaga Carlos L, Park So Yeon, Michor Franziska, Polyak Kornelia, In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer, Nature Genetics, 47, 10, 2015. Crossref

  24. Alaoui-Jamali Moulay A., Morand Grégoire B., da Silva Sabrina Daniela, ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics, Frontiers in Genetics, 6, 2015. Crossref

  25. Lin Chun-Han, Pelissier Fanny A., Zhang Hui, Lakins Jon, Weaver Valerie M., Park Catherine, LaBarge Mark A., Luo Kunxin, Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors, Molecular Biology of the Cell, 26, 22, 2015. Crossref

  26. Puglisi Fabio, Fontanella Caterina, Amoroso Vito, Bianchi Giulia Valeria, Bisagni Giancarlo, Falci Cristina, Fontana Andrea, Generali Daniele, Gianni Lorenzo, Grassadonia Antonio, Moscetti Luca, Portarena Ilaria, Rossi Emanuela, Marchetti Paolo, Current challenges in HER2-positive breast cancer, Critical Reviews in Oncology/Hematology, 98, 2016. Crossref

  27. Abravanel Daniel L., Belka George K., Pan Tien-chi, Pant Dhruv K., Collins Meredith A., Sterner Christopher J., Chodosh Lewis A., Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy, Journal of Clinical Investigation, 125, 6, 2015. Crossref

  28. Bazargani Y. T., de Boer A., Schellens J. H. M., Leufkens H. G. M., Mantel-Teeuwisse Aukje K., Essential medicines for breast cancer in low and middle income countries, BMC Cancer, 15, 1, 2015. Crossref

  29. Millis Sherri Z., Gatalica Zoran, Winkler Josiah, Vranic Semir, Kimbrough Jeffery, Reddy Sandeep, O'Shaughnessy Joyce A., Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications, Clinical Breast Cancer, 15, 6, 2015. Crossref

  30. Stuhlmiller Timothy J., Miller Samantha M., Zawistowski Jon S., Nakamura Kazuhiro, Beltran Adriana S., Duncan James S., Angus Steven P., Collins Kyla A.L., Granger Deborah A., Reuther Rachel A., Graves Lee M., Gomez Shawn M., Kuan Pei-Fen, Parker Joel S., Chen Xin, Sciaky Noah, Carey Lisa A., Earp H. Shelton, Jin Jian, Johnson Gary L., Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains, Cell Reports, 11, 3, 2015. Crossref

  31. Chang Li-Yun, Liu Li-Yu D., Roth Don A., Kuo Wen-Hung, Hwa Hsiao-Lin, Chang King-Jen, Hsieh Fon-Jou, The Major Prognostic Features of Nuclear ReceptorNR5A2in Infiltrating Ductal Breast Carcinomas, International Journal of Genomics, 2015, 2015. Crossref

  32. van Vuuren Rustelle Janse, Visagie Michelle H., Theron Anne E., Joubert Annie M., Antimitotic drugs in the treatment of cancer, Cancer Chemotherapy and Pharmacology, 76, 6, 2015. Crossref

  33. Sun Zijia, Shi Yaqin, Shen Yan, Cao Lulu, Zhang Wenwen, Guan Xiaoxiang, Analysis of different HER ‐2 mutations in breast cancer progression and drug resistance , Journal of Cellular and Molecular Medicine, 19, 12, 2015. Crossref

  34. Agajanian Megan, Runa Farhana, Kelber Jonathan A., Identification of a PEAK1/ZEB1 signaling axis during TGFβ/fibronectin-induced EMT in breast cancer, Biochemical and Biophysical Research Communications, 465, 3, 2015. Crossref

  35. Tripathy Debu, The BMC Medicine breast cancer collection: an illustration of contemporary research and clinical care, BMC Medicine, 13, 1, 2015. Crossref

  36. Shah Deep, Osipo Clodia, Cancer stem cells and HER2 positive breast cancer: The story so far, Genes & Diseases, 3, 2, 2016. Crossref

  37. Lim Bora, Hortobagyi Gabriel N., Current challenges of metastatic breast cancer, Cancer and Metastasis Reviews, 35, 4, 2016. Crossref

  38. Dinh Phuong, Piccart Martine J., HER2-Targeted Therapy, in Management of Breast Diseases, 2016. Crossref

  39. Tilio Martina, Gambini Valentina, Wang Junbiao, Garulli Chiara, Kalogris Cristina, Andreani Cristina, Bartolacci Caterina, Elexpuru Zabaleta Maria, Pietrella Lucia, Hysi Albana, Iezzi Manuela, Belletti Barbara, Orlando Fiorenza, Provinciali Mauro, Galeazzi Roberta, Marchini Cristina, Amici Augusto, Irreversible inhibition of Δ16HER2 is necessary to suppress Δ16HER2-positive breast carcinomas resistant to Lapatinib, Cancer Letters, 381, 1, 2016. Crossref

  40. Lv Quanxia, Meng Ziyuan, Yu Yuanyuan, Jiang Feng, Guan Daogang, Liang Chao, Zhou Junwei, Lu Aiping, Zhang Ge, Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer, International Journal of Molecular Sciences, 17, 12, 2016. Crossref

  41. Gomes Bruno Costa, Santos Bruno, Rueff José, Rodrigues António Sebastião, Methods for Studying MicroRNA Expression and Their Targets in Formalin-Fixed, Paraffin-Embedded (FFPE) Breast Cancer Tissues, in Cancer Drug Resistance, 1395, 2016. Crossref

  42. Denny Erin C., Kane Susan E., Tan Ming, t-Darpp Promotes Enhanced EGFR Activation and New Drug Synergies in Her2-Positive Breast Cancer Cells, PLOS ONE, 10, 6, 2015. Crossref

  43. Fasolo Angelica, Gianni Luca, Introduction and background biology, in Handbook of HER2-Targeted Agents in Breast Cancer, 2016. Crossref

  44. Pera Elena, Kaemmerer Elke, Milevskiy Michael J. G., Yapa Kunsala T. D. S., O’Donnell Jake S., Brown Melissa A., Simpson Fiona, Peters Amelia A., Roberts-Thomson Sarah J., Monteith Gregory R., The voltage gated Ca2+-channel Cav3.2 and therapeutic responses in breast cancer, Cancer Cell International, 16, 1, 2016. Crossref

  45. Gasch Christin, Oldopp Theresa, Mauermann Oliver, Gorges Tobias M., Andreas Antje, Coith Cornelia, Müller Volkmar, Fehm Tanja, Janni Wolfgang, Pantel Klaus, Riethdorf Sabine, Frequent detection ofPIK3CAmutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer, Molecular Oncology, 10, 8, 2016. Crossref

  46. CRAFTER CLAIRE, VINCENT JOHN P., TANG ERIC, DUDLEY PHILLIPPA, JAMES NEIL H., KLINOWSKA TERESA, DAVIES BARRY R., Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models, International Journal of Oncology, 47, 2, 2015. Crossref

  47. Goh Gerald, Schmid Ramona, Guiver Kelly, Arpornwirat Wichit, Chitapanarux Imjai, Ganju Vinod, Im Seock-Ah, Kim Sung-Bae, Dechaphunkul Arunee, Maneechavakajorn Jedzada, Spector Neil, Yau Thomas, Afrit Mehdi, Ahmed Slim Ben, Johnston Stephen R., Gibson Neil, Uttenreuther-Fischer Martina, Herrero Javier, Swanton Charles, Beck Andrew H., Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine, PLOS Medicine, 13, 12, 2016. Crossref

  48. Walsh Louise, Gallagher William M., O’Connor Darran P., Ní Chonghaile Tríona, Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer, Expert Review of Molecular Diagnostics, 16, 5, 2016. Crossref

  49. PACHECO-VELÁZQUEZ SILVIA CECILIA, GALLARDO-PÉREZ JUAN CARLOS, AGUILAR-PONCE JOSÉ LUIS, VILLARREAL PATRICIA, RUIZ-GODOY LUZ, PÉREZ-SÁNCHEZ MANUEL, MARÍN-HERNÁNDEZ ALVARO, RUIZ-GARCÍA ERIKA, MENESES-GARCÍA ABELARDO, MORENO-SÁNCHEZ RAFAEL, RODRÍGUEZ-ENRÍQUEZ SARA, Identification of a metabolic and canonical biomarker signature in Mexican HR+/HER2−, triple positive and triple-negative breast cancer patients, International Journal of Oncology, 45, 6, 2014. Crossref

  50. Dragowska Wieslawa H., Weppler Sherry A., Wang Jun Chih, Wong Ling Yan, Kapanen Anita I., Rawji Jenna S., Warburton Corinna, Qadir Mohammed A., Donohue Elizabeth, Roberge Michel, Gorski Sharon M., Gelmon Karen A., Bally Marcel B., Velasco Guillermo, Induction of Autophagy Is an Early Response to Gefitinib and a Potential Therapeutic Target in Breast Cancer, PLoS ONE, 8, 10, 2013. Crossref

  51. Lousberg Laurence, Collignon Joëlle, Jerusalem Guy, Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies, Therapeutic Advances in Medical Oncology, 8, 6, 2016. Crossref

  52. Zhang Liang, Huang Yi, Zhuo Wenlei, Zhu Yi, Zhu Bo, Chen Zhengtang, Identification and characterization of biomarkers and their functions for Lapatinib-resistant breast cancer, Medical Oncology, 34, 5, 2017. Crossref

  53. Sahni Jennifer M., Keri Ruth A., Targeting bromodomain and extraterminal proteins in breast cancer, Pharmacological Research, 129, 2018. Crossref

  54. Ferreira Paulo Michel Pinheiro, Pessoa Cláudia, Molecular biology of human epidermal receptors, signaling pathways and targeted therapy against cancers: new evidences and old challenges, Brazilian Journal of Pharmaceutical Sciences, 53, 2, 2017. Crossref

  55. Azad A. K. M., Lawen Alfons, Keith Jonathan M., Ahmad Aamir, Bayesian model of signal rewiring reveals mechanisms of gene dysregulation in acquired drug resistance in breast cancer, PLOS ONE, 12, 3, 2017. Crossref

  56. Rosenbaum Jason N., Weisman Paul, The Evolving Role of Companion Diagnostics for Breast Cancer in an Era of Next-Generation Omics, The American Journal of Pathology, 187, 10, 2017. Crossref

  57. Bastos Nuno, Ruivo Carolina F., da Silva Soraia, Melo Sonia A., Exosomes in cancer: Use them or target them?, Seminars in Cell & Developmental Biology, 78, 2018. Crossref

  58. Muntasell Aura, Cabo Mariona, Servitja Sonia, Tusquets Ignasi, Martínez-García María, Rovira Ana, Rojo Federico, Albanell Joan, López-Botet Miguel, Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy, Frontiers in Immunology, 8, 2017. Crossref

  59. Buzatto I.P.C., Ribeiro-Silva A., Andrade J.M., Carrara H.H.A., Silveira W.A., Tiezzi D.G., Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors, Brazilian Journal of Medical and Biological Research, 50, 2, 2017. Crossref

  60. Chapa Joaquin, Bourgo Ryan J., Greene Geoffrey L., Kulkarni Swati, An Gary, Tan Ming, Examining the Pathogenesis of Breast Cancer Using a Novel Agent-Based Model of Mammary Ductal Epithelium Dynamics, PLoS ONE, 8, 5, 2013. Crossref

  61. Brufsky Adam M., Current Approaches and Emerging Directions in HER2-resistant Breast Cancer, Breast Cancer: Basic and Clinical Research, 8, 2014. Crossref

  62. HEIN ASHLEY L., OUELLETTE MICHEL M., YAN YING, Radiation-induced signaling pathways that promote cancer cell survival (Review), International Journal of Oncology, 45, 5, 2014. Crossref

  63. Schwarz Luis J, Hutchinson Katherine E, Rexer Brent N, Estrada Mónica Valeria, Gonzalez Ericsson Paula I, Sanders Melinda E, Dugger Teresa C, Formisano Luigi, Guerrero-Zotano Angel, Red-Brewer Monica, Young Christian D, Lantto Johan, Pedersen Mikkel W, Kragh Michael, Horak Ivan D, Arteaga Carlos L, An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression, JNCI: Journal of the National Cancer Institute, 109, 11, 2017. Crossref

  64. Rimawi Mothaffar F., De Angelis Carmine, Contreras Alejandro, Pareja Fresia, Geyer Felipe C., Burke Kathleen A., Herrera Sabrina, Wang Tao, Mayer Ingrid A., Forero Andres, Nanda Rita, Goetz Matthew P., Chang Jenny C., Krop Ian E., Wolff Antonio C., Pavlick Anne C., Fuqua Suzanne A. W., Gutierrez Carolina, Hilsenbeck Susan G., Li Marilyn M., Weigelt Britta, Reis-Filho Jorge S., Kent Osborne C., Schiff Rachel, Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer, Breast Cancer Research and Treatment, 167, 3, 2018. Crossref

  65. Veeraraghavan Jamunarani, De Angelis Carmine, Reis-Filho Jorge S., Pascual Tomás, Prat Aleix, Rimawi Mothaffar F., Osborne C. Kent, Schiff Rachel, De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance, The Breast, 34, 2017. Crossref

  66. Tormo Eduardo, Adam-Artigues Anna, Ballester Sandra, Pineda Begoña, Zazo Sandra, González-Alonso Paula, Albanell Joan, Rovira Ana, Rojo Federico, Lluch Ana, Eroles Pilar, The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene, Scientific Reports, 7, 1, 2017. Crossref

  67. Du Juan, Yu Yu, Zhan Jun, Zhang Hongquan, Targeted Therapies Against Growth Factor Signaling in Breast Cancer, in Translational Research in Breast Cancer, 1026, 2017. Crossref

  68. Wang Ya-Wei, Zhang Hai-Yan, Li Ji-Sheng, Wang Xiu-Wen, Integrated Exploitation of the Structural Diversity Space of Chemotherapy Drugs to Selectively Inhibit HER2 T798M Mutant in Lung Cancer, Chemistry & Biodiversity, 14, 3, 2017. Crossref

  69. He Licai, Du Zhuanyun, Xiong Xusheng, Ma Hua, Zhu Zhenfeng, Gao Hongwei, Cao Jiawei, Li Tong, Li Hongzhi, Yang Kaiyan, Chen Guorong, Richer Jennifer K., Gu Haihua, Targeting Androgen Receptor in Treating HER2 Positive Breast Cancer, Scientific Reports, 7, 1, 2017. Crossref

  70. Mortlock A.A., Wilson D.M., Kettle J.G., Goldberg F.W., Foote K.M., Selective Kinase Inhibitors in Cancer, in Comprehensive Medicinal Chemistry III, 2017. Crossref

  71. Masoud Viviana, Pagès Gilles, Targeted therapies in breast cancer: New challenges to fight against resistance, World Journal of Clinical Oncology, 8, 2, 2017. Crossref

  72. Schwartz Alyssa D., Barney Lauren E., Jansen Lauren E., Nguyen Thuy V., Hall Christopher L., Meyer Aaron S., Peyton Shelly R., A biomaterial screening approach reveals microenvironmental mechanisms of drug resistance, Integrative Biology, 9, 12, 2017. Crossref

  73. Lu Ji, Zhou Kun, Yin Xiaoxing, Xu Han, Ma Baojin, Molecular insight into the T798M gatekeeper mutation-caused acquired resistance to tyrosine kinase inhibitors in ErbB2-positive breast cancer, Computational Biology and Chemistry, 78, 2019. Crossref

  74. Sharifi Marina N., O'Regan Ruth M., Novel Non–HER2-targeted Therapies in HER2+ Breast Cancer, in Her2-Positive Breast Cancer, 2019. Crossref

  75. Vorobyeva Anzhelika, Westerlund Kristina, Mitran Bogdan, Altai Mohamed, Rinne Sara, Sörensen Jens, Orlova Anna, Tolmachev Vladimir, Karlström Amelie Eriksson, Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy, Scientific Reports, 8, 1, 2018. Crossref

  76. Miller Elizabeth, Lee Hee Jin, Lulla Amriti, Hernandez Liz, Gokare Prashanth, Lim Bora, Current treatment of early breast cancer: adjuvant and neoadjuvant therapy, F1000Research, 3, 2014. Crossref

  77. Schedin Troy B., Borges Virginia F., Shagisultanova Elena, Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition, International Journal of Breast Cancer, 2018, 2018. Crossref

  78. Liu Wenhu, Yuan Jiangbei, Liu Zhenzhong, Zhang Jianwu, Chang Jinxia, Label-Free Quantitative Proteomics Combined with Biological Validation Reveals Activation of Wnt/β-Catenin Pathway Contributing to Trastuzumab Resistance in Gastric Cancer, International Journal of Molecular Sciences, 19, 7, 2018. Crossref

  79. Lote Hazel, Valeri Nicola, Chau Ian, HER2 inhibition in gastro-oesophageal cancer: A review drawing on lessons learned from breast cancer, World Journal of Gastrointestinal Oncology, 10, 7, 2018. Crossref

  80. Creedon Helen, Balderstone Lucy A, Muir Morwenna, Balla Jozef, Gomez-Cuadrado Laura, Tracey Natasha, Loane Joseph, Klinowska Teresa, Muller William J, Brunton Valerie G, Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer, Disease Models & Mechanisms, 2015. Crossref

  81. Nguyen Ngoc, Nguyen Ngoc, Tran Ngo, Le Phung, Nguyen Thi, Nguyen Ngoc, Bach Long, Doan Vu, Tran Ha, Le Van, Tran Ngoc, Synergic Activity Against MCF-7 Breast Cancer Cell Growth of Nanocurcumin-Encapsulated and Cisplatin-Complexed Nanogels, Molecules, 23, 12, 2018. Crossref

  82. Koutras Angelos, Lazaridis Georgios, Koliou Georgia-Angeliki, Kouvatseas George, Christodoulou Christos, Pectasides Dimitrios, Kotoula Vassiliki, Batistatou Anna, Bobos Mattheos, Tsolaki Eleftheria, Papadopoulou Kyriaki, Pentheroudakis George, Papakostas Pavlos, Pervana Stavroula, Petraki Kalliopi, Chrisafi Sofia, Razis Evangelia, Psyrri Amanda, Bafaloukos Dimitrios, Kalogeras Konstantine T., Kalofonos Haralambos P., Fountzilas George, Ahmad Aamir, Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study, PLOS ONE, 13, 12, 2018. Crossref

  83. Isidori Federica, Malvi Deborah, Fittipaldi Silvia, Forcato Claudio, Bozzarelli Isotta, Sala Claudia, Raulli Giovanni, D’Errico Antonia, Fiorentino Michelangelo, Seri Marco, Krishnadath Kausilia K., Bonora Elena, Mattioli Sandro, Genomic profiles of primary and metastatic esophageal adenocarcinoma identified via digital sorting of pure cell populations: results from a case report, BMC Cancer, 18, 1, 2018. Crossref

  84. Shi Kai, Fang Yan, Gao Shan, Yang Dongjuan, Bi Hongshu, Xue Jianxiu, Lu Anqi, Li Yuai, Ke Liyuan, Lin Xiaojie, Jin Xuechao, Li Min, Inorganic kernel - Supported asymmetric hybrid vesicles for targeting delivery of STAT3-decoy oligonucleotides to overcome anti-HER2 therapeutic resistance of BT474R, Journal of Controlled Release, 279, 2018. Crossref

  85. Butti Ramesh, Das Sumit, Gunasekaran Vinoth Prasanna, Yadav Amit Singh, Kumar Dhiraj, Kundu Gopal C., Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges, Molecular Cancer, 17, 1, 2018. Crossref

  86. Soto-Perez-De-Celis Enrique, Loh Kah Poh, Baldini Capucine, Battisti Nicolò Matteo Luca, Chavarri-Guerra Yanin, De Glas Nienke A., Hsu Tina, Hurria Arti, Targeted agents for HER2-positive breast cancer in older adults: current and future perspectives, Expert Opinion on Investigational Drugs, 27, 10, 2018. Crossref

  87. Blasco-Benito Sandra, Seijo-Vila Marta, Caro-Villalobos Miriam, Tundidor Isabel, Andradas Clara, García-Taboada Elena, Wade Jeff, Smith Stewart, Guzmán Manuel, Pérez-Gómez Eduardo, Gordon Mara, Sánchez Cristina, Appraising the “entourage effect”: Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer, Biochemical Pharmacology, 157, 2018. Crossref

  88. Siravegna Giulia, Lazzari Luca, Crisafulli Giovanni, Sartore-Bianchi Andrea, Mussolin Benedetta, Cassingena Andrea, Martino Cosimo, Lanman Richard B., Nagy Rebecca J., Fairclough Stephen, Rospo Giuseppe, Corti Giorgio, Bartolini Alice, Arcella Pamela, Montone Monica, Lodi Francesca, Lorenzato Annalisa, Vanzati Alice, Valtorta Emanuele, Cappello Giovanni, Bertotti Andrea, Lonardi Sara, Zagonel Vittorina, Leone Francesco, Russo Mariangela, Balsamo Antonella, Truini Mauro, Di Nicolantonio Federica, Amatu Alessio, Bonazzina Erica, Ghezzi Silvia, Regge Daniele, Vanzulli Angelo, Trusolino Livio, Siena Salvatore, Marsoni Silvia, Bardelli Alberto, Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer, Cancer Cell, 34, 1, 2018. Crossref

  89. Wang Manni, Hu Yuzhu, Yu Ting, Ma Xuelei, Wei Xiawei, Wei Yuquan, Pan-HER-targeted approach for cancer therapy: Mechanisms, recent advances and clinical prospect, Cancer Letters, 439, 2018. Crossref

  90. Rizzolio Sabrina, Cagnoni Gabriella, Battistini Chiara, Bonelli Stefano, Isella Claudio, Van Ginderachter Jo A., Bernards René, Di Nicolantonio Federica, Giordano Silvia, Tamagnone Luca, Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies, Journal of Clinical Investigation, 128, 9, 2018. Crossref

  91. Martínez-Pérez Carlos, Turnbull Arran K, Dixon J Michael, The evolving role of receptors as predictive biomarkers for metastatic breast cancer, Expert Review of Anticancer Therapy, 19, 2, 2019. Crossref

  92. Brinda Bryan, Khan Irum, Parkin Brian, Konig Heiko, The rocky road to personalized medicine in acute myeloid leukaemia, Journal of Cellular and Molecular Medicine, 22, 3, 2018. Crossref

  93. Rosenzweig Steven A., , 138, 2018. Crossref

  94. Hoorens Mark W.H., Szymanski Wiktor, Reversible, Spatial and Temporal Control over Protein Activity Using Light, Trends in Biochemical Sciences, 43, 8, 2018. Crossref

  95. Vaidya Tanaya, Straubinger Robert M., Ait-Oudhia Sihem, Development and Evaluation of Tri-Functional Immunoliposomes for the Treatment of HER2 Positive Breast Cancer, Pharmaceutical Research, 35, 5, 2018. Crossref

  96. Nami Babak, Maadi Hamid, Wang Zhixiang, Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer, Cancers, 10, 10, 2018. Crossref

  97. Andrade Silmara N., Evangelista Fernanda C. G., Seckler Diego, Marques Deisielly R., Freitas Túlio R., Nunes Renata R., Oliveira Júlia T., Ribeiro Rosy I. M. A., Santos Hélio B., Thomé Ralph G., Taranto Alex G., Santos Fabio V., Viana Gustavo H. R., Freitas Rossimiriam P., Humberto Jorge L., Sabino Adriano de P., Hilário Flaviane F., Varotti Fernando P., Synthesis, cytotoxic activity, and mode of action of new Santacruzamate A analogs, Medicinal Chemistry Research, 27, 11-12, 2018. Crossref

  98. Namba Masashi, Hattori Noboru, Hamada Hironobu, Yamaguchi Kakuhiro, Okamoto Yohei, Nakashima Taku, Masuda Takeshi, Sakamoto Shinjiro, Horimasu Yasushi, Miyamoto Shintaro, Iwamoto Hiroshi, Fujitaka Kazunori, Kohno Nobuoki, Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1, Cancer Letters, 442, 2019. Crossref

  99. Wang Jun-wei, Deng Ya-ting, Chu Han, Wang Juan, Hu Yong, Lin Zhi-hua, 3D-QSAR, molecular docking, and new compound design of pyrimidine derivatives as Src small molecule inhibitors, Medicinal Chemistry Research, 28, 8, 2019. Crossref

  100. Chen Zhanhong, Sun Tian, Yang Ziyan, Zheng Yabing, Yu Ruoying, Wu Xue, Yan Junrong, Shao Yang W, Shao Xiying, Cao Wenming, Wang Xiaojia, Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling, Molecular Genetics & Genomic Medicine, 8, 2, 2020. Crossref

  101. Nicolini Andrea, Barak Vivian, Biava Piermario, Ferrari Paola, Rossi Giuseppe, Carpi Angelo, The Use of Immunotherapy to Treat Metastatic Breast Cancer, Current Medicinal Chemistry, 26, 6, 2019. Crossref

  102. Ngamcherdtrakul Worapol, Yantasee Wassana, siRNA therapeutics for breast cancer: recent efforts in targeting metastasis, drug resistance, and immune evasion, Translational Research, 214, 2019. Crossref

  103. Koschorke Ada, Faraci Simona, Giani Debora, Chiodoni Claudia, Iorio Egidio, Canese Rossella, Colombo Mario P., Lamolinara Alessia, Iezzi Manuela, Ladomery Michael, Vernieri Claudio, de Braud Filippo, Di Nicola Massimo, Tagliabue Elda, Castagnoli Lorenzo, Pupa Serenella M., Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment, Cellular Oncology, 42, 6, 2019. Crossref

  104. Erickson Britt K., Zeybek Burak, Santin Alessandro D., Fader Amanda N., Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies, Current Opinion in Obstetrics & Gynecology, 32, 1, 2020. Crossref

  105. Hao Yue, Yu Xinchao, Bai Yonghong, McBride Helen J., Huang Xin, Xu Wenqing, Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex, PLOS ONE, 14, 5, 2019. Crossref

  106. Liu Baoquan, Su Fei, Lv Xiaohong, Zhang Wenbo, Shang Xiaochen, Zhang Yafang, Zhang Jianguo, Serum microRNA-21 predicted treatment outcome and survival in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy combined with trastuzumab, Cancer Chemotherapy and Pharmacology, 84, 5, 2019. Crossref

  107. Jodlowski Tomasz, Ramesh K. H., Molecular Pathway and Fluorescence In Situ Hybridization Testing of ERBB2 (HER2) Gene Amplification in Invasive Ductal Carcinoma of Breast, in Molecular Diagnostics in Cancer Patients, 2019. Crossref

  108. Brennan Matthew, Lim Bora, The Actual Role of Receptors as Cancer Markers, Biochemical and Clinical Aspects: Receptors in Breast Cancer, in Advances in Cancer Biomarkers, 867, 2015. Crossref

  109. Song Moo-Kon, Park Byeong-Bae, Uhm Ji-Eun, Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies, International Journal of Molecular Sciences, 20, 20, 2019. Crossref

  110. Aziz Saba Wasim, Aziz Moammir Hasan, Major Signaling Pathways Involved in Breast Cancer, in Breast Cancer Metastasis and Drug Resistance, 2013. Crossref

  111. Lima Zeinab Safarpour, Ghadamzadeh Mostafa, Arashloo Farzad Tahmasebi, Amjad Ghazaleh, Ebadi Mohammad Reza, Younesi Ladan, Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms, Journal of Hematology & Oncology, 12, 1, 2019. Crossref

  112. Nava Miguel, Dutta Pranabananda, Zemke Nathan R., Farias-Eisner Robin, Vadgama Jaydutt V., Wu Yanyuan, Transcriptomic and ChIP-sequence interrogation of EGFR signaling in HER2+ breast cancer cells reveals a dynamic chromatin landscape and S100 genes as targets, BMC Medical Genomics, 12, 1, 2019. Crossref

  113. Veeraraghavan J., De Angelis C., Mao R., Wang T., Herrera S., Pavlick A.C., Contreras A., Nuciforo P., Mayer I.A., Forero A., Nanda R., Goetz M.P., Chang J.C., Wolff A.C., Krop I.E., Fuqua S.A.W., Prat A., Hilsenbeck S.G., Weigelt B., Reis-Filho J.S., Gutierrez C., Osborne C.K., Rimawi M.F., Schiff R., A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer, Annals of Oncology, 30, 6, 2019. Crossref

  114. He Qinghua, Liu Zhaoyu, Liu Zhihua, Lai Yuxiong, Zhou Xinke, Weng Jinsheng, TCR-like antibodies in cancer immunotherapy, Journal of Hematology & Oncology, 12, 1, 2019. Crossref

  115. Pagliarini Raymond, Shao Wenlin, Sellers William R, Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure, EMBO reports, 16, 3, 2015. Crossref

  116. Wang Jiani, Xu Binghe, Targeted therapeutic options and future perspectives for HER2-positive breast cancer, Signal Transduction and Targeted Therapy, 4, 1, 2019. Crossref

  117. Chu Pei-Yu, Tai Yu-Ling, Shen Tang-Long, Grb7, a Critical Mediator of EGFR/ErbB Signaling, in Cancer Development and as a Potential Therapeutic Target, Cells, 8, 5, 2019. Crossref

  118. Nava Miguel, Dutta Pranabananda, Farias-Eisner Robin, Vadgama Jaydutt V., Wu Yanyuan, Utilization of NGS technologies to investigate transcriptomic and epigenomic mechanisms in trastuzumab resistance, Scientific Reports, 9, 1, 2019. Crossref

  119. Showalter Loral E., Oechsle Crystal, Ghimirey Nirmala, Steele Chase, Czerniecki Brian J., Koski Gary K., Ahmad Aamir, Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib, PLOS ONE, 14, 1, 2019. Crossref

  120. Fedele Palma, Sanna Valeria, Fancellu Alessandro, Cinieri Saverio, A clinical evaluation of treatments that target cell cycle machinery in breast cancer, Expert Opinion on Pharmacotherapy, 20, 18, 2019. Crossref

  121. Goutsouliak Kristina, Veeraraghavan Jamunarani, Sethunath Vidyalakshmi, De Angelis Carmine, Osborne C. Kent, Rimawi Mothaffar F., Schiff Rachel, Towards personalized treatment for early stage HER2-positive breast cancer, Nature Reviews Clinical Oncology, 17, 4, 2020. Crossref

  122. Ouellette Michel M., Yan Ying, Radiation‐activated prosurvival signaling pathways in cancer cells, Precision Radiation Oncology, 3, 3, 2019. Crossref

  123. Lu Qiong, Wang Lingfei, Zhang Yajun, Yu Xiaojie, Wang Chao, Wang Huajing, Yang Yang, Chong Xiaodan, Xia Tian, Meng Yanchun, Wang Yuxiao, Lu Cuihua, Zhou Lijun, Li Bohua, An anti-ErbB2 fully human antibody circumvents trastuzumab resistance, Oncotarget, 7, 41, 2016. Crossref

  124. Padmanabhan Regina, Kheraldine Hadeel Shafeeq, Meskin Nader, Vranic Semir, Al Moustafa Ala-Eddin, Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models, Cancers, 12, 3, 2020. Crossref

  125. Malapelle Umberto, Muscarella Lucia Anna, Pisapia Pasquale, Rossi Antonio, Targeting emerging molecular alterations in the treatment of non-small cell lung cancer: current challenges and the way forward, Expert Opinion on Investigational Drugs, 29, 4, 2020. Crossref

  126. Sahai Vaibhav, Redig Amanda J., Collier Katharine A., Eckerdt Frank D., Munshi Hidayatullah G., Targeting BET bromodomain proteins in solid tumors, Oncotarget, 7, 33, 2016. Crossref

  127. Karakashev Sergey V., Reginato Mauricio J., Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2, Oncotarget, 6, 4, 2015. Crossref

  128. Huang Wei-Chien, Hung Chao-Ming, Wei Ching-Ting, Chen Tsung-Ming, Chien Pei-Hsuan, Pan Hsiao-Lin, Lin Yueh-Ming, Chen Yun-Ju, Interleukin-6 expression contributes to lapatinib resistance through maintenance of stemness property in HER2-positive breast cancer cells, Oncotarget, 7, 38, 2016. Crossref

  129. Lyu Hui, Yang Xiao He, Edgerton Susan M., Thor Ann D., Wu Xiaoying, He Zhimin, Liu Bolin, The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells, Oncotarget, 7, 3, 2016. Crossref

  130. Jain Sidhant, Kumar Sahil, Cancer immunotherapy: dawn of the death of cancer?, International Reviews of Immunology, 39, 5, 2020. Crossref

  131. Creedon Helen, Gómez-Cuadrado Laura, Tarnauskaitė Žygimantė, Balla Jozef, Canel Marta, MacLeod Kenneth G., Serrels Bryan, Fraser Craig, Unciti-Broceta Asier, Tracey Natasha, Le Bihan Thierry, Klinowska Teresa, Sims Andrew H., Byron Adam, Brunton Valerie G., Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy, Oncotarget, 7, 10, 2016. Crossref

  132. Wang Chao, Wang Lingfei, Yu Xiaojie, Zhang Yajun, Meng Yanchun, Wang Huajing, Yang Yang, Gao Jie, Wei Huafeng, Zhao Jian, Lu Cuihua, Chen Han, Sun Yanping, Li Bohua, Combating acquired resistance to trastuzumab by an anti-ErbB2 fully human antibody, Oncotarget, 8, 26, 2017. Crossref

  133. De Mattos-Arruda Leticia, Bottai Giulia, Nuciforo Paolo G., Di Tommaso Luca, Giovannetti Elisa, Peg Vicente, Losurdo Agnese, Pérez-Garcia José, Masci Giovanna, Corsi Fabio, Cortés Javier, Seoane Joan, Calin George A., Santarpia Libero, MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients, Oncotarget, 6, 35, 2015. Crossref

  134. Brown Wells S., Akhand Saeed Salehin, Wendt Michael K., FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition, Oncotarget, 7, 50, 2016. Crossref

  135. Ben-Shmuel Aviad, Biber Guy, Barda-Saad Mira, Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?, Frontiers in Immunology, 11, 2020. Crossref

  136. Sinevici Nicoleta, Ataeinia Bahar, Zehnder Veronica, Lin Kevin, Grove Lauren, Heidari Pedram, Mahmood Umar, HER3 Differentiates Basal From Claudin Type Triple Negative Breast Cancer and Contributes to Drug and Microenvironmental Induced Resistance, Frontiers in Oncology, 10, 2020. Crossref

  137. Baliu-Piqué Mariona, Pandiella Atanasio, Ocana Alberto, Breast Cancer Heterogeneity and Response to Novel Therapeutics, Cancers, 12, 11, 2020. Crossref

  138. Roscigno Giuseppina, Scognamiglio Iolanda, Ingenito Francesco, Chianese Rosario Vincenzo, Palma Francesco, Chan Alan, Condorelli Gerolama, Modulating the Crosstalk between the Tumor and the Microenvironment Using SiRNA: A Flexible Strategy for Breast Cancer Treatment, Cancers, 12, 12, 2020. Crossref

  139. Wang Junbiao, Iannarelli Romilde, Pucciarelli Stefania, Laudadio Emiliano, Galeazzi Roberta, Giangrossi Mara, Falconi Maurizio, Cui Lishan, Navia Aleix Marti, Buccioni Michela, Marucci Gabriella, Tomassoni Daniele, Serini Laura, Sut Stefania, Maggi Filippo, Dall’Acqua Stefano, Marchini Cristina, Amici Augusto, Acetylshikonin isolated from Lithospermum erythrorhizon roots inhibits dihydrofolate reductase and hampers autochthonous mammary carcinogenesis in Δ16HER2 transgenic mice, Pharmacological Research, 161, 2020. Crossref

  140. Abdullah Ammara, Akhand Saeed Salehin, Paez Juan Sebastian Paez, Brown Wells, Pan Li, Libring Sarah, Badamy Michael, Dykuizen Emily, Solorio Luis, Andy Tao W., Wendt Michael K., Epigenetic targeting of neuropilin-1 prevents bypass signaling in drug-resistant breast cancer, Oncogene, 40, 2, 2021. Crossref

  141. Pedroza Diego A., Rajamanickam Venkatesh, Subramani Ramadevi, Bencomo Alejandra, Galvez Adriana, Lakshmanaswamy Rajkumar, Progesterone receptor membrane component 1 promotes the growth of breast cancers by altering the phosphoproteome and augmenting EGFR/PI3K/AKT signalling, British Journal of Cancer, 123, 8, 2020. Crossref

  142. Henry N. Lynn, Shah Payal D., Haider Irfanullah, Freer Phoebe E., Jagsi Reshma, Sabel Michael S., Cancer of the Breast, in Abeloff's Clinical Oncology, 2020. Crossref

  143. Gillman Jennifer A., Pantel Austin R., Mankoff David A., Edmonds Christine E., Update on Quantitative Imaging for Predicting and Assessing Response in Oncology, Seminars in Nuclear Medicine, 50, 6, 2020. Crossref

  144. Witkiewicz Agnieszka K., Cox Derek, Knudsen Erik S., CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models, Genes & Cancer, 5, 7-8, 2014. Crossref

  145. Santarpia Libero, Bottai Giulia, Kelly Catherine M., Győrffy Balázs, Székely Borbala, Pusztai Lajos, Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer, The Oncologist, 21, 9, 2016. Crossref

  146. Lee Changhee, Park Inseok, Kim Jungbin, Cho Hyunjin, Yang Keunho, Lee Yujin, Park Kyeongmee, Kim Jiyoung, Shin Youngjoo, Gwak Geumhee, Characteristics of HER2-Positive Breast Cancer according to HER2 2+/ Low or 3+/High Classification by Immunohistochemistry Assay: Study of 205 Cases Treated in a Single Center, Journal of Breast Disease, 9, 1, 2021. Crossref

  147. Menon Rajasree, Panwar Bharat, Eksi Ridvan, Kleer Celina, Guan Yuanfang, Omenn Gilbert S., Computational Inferences of the Functions of Alternative/Noncanonical Splice Isoforms Specific to HER2+/ER–/PR– Breast Cancers, a Chromosome 17 C-HPP Study, Journal of Proteome Research, 14, 9, 2015. Crossref

  148. Creedon Helen, Byron Adam, Main Joanna, Hayward Larry, Klinowska Teresa, Brunton Valerie G., Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer, Biochemical Society Transactions, 42, 4, 2014. Crossref

  149. Chen Yi-Li, Cui Yue, Liu Xinyuan, Liu Guojian, Dong Xingchen, Tang Lei, Hung Yifeng, Wang Chunhe, Feng Mei-Qing, A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy, Journal of Biological Chemistry, 297, 6, 2021. Crossref

  150. Wang Bo-Wei, Huang Chih-Hao, Liu Liang-Chih, Cheng Fang-Ju, Wei Ya-Ling, Lin Yueh-Ming, Wang Yu-Fei, Wei Ching-Ting, Chen Yeh, Chen Yun-Ju, Huang Wei-Chien, Pim1 Kinase Inhibitors Exert Anti-Cancer Activity Against HER2-Positive Breast Cancer Cells Through Downregulation of HER2, Frontiers in Pharmacology, 12, 2021. Crossref

  151. Yang Yongguang, Leonard Marissa, Luo Zhenhua, Yeo Syn, Bick Gregory, Hao Mingang, Cai Chunmiao, Charif Mahmoud, Wang Jiang, Guan Jun-Lin, Lower Elyse E., Zhang Xiaoting, Functional cooperation between co-amplified genes promotes aggressive phenotypes of HER2-positive breast cancer, Cell Reports, 34, 10, 2021. Crossref

  152. Angus Steven P., Stuhlmiller Timothy J., Mehta Gaurav, Bevill Samantha M., Goulet Daniel R., Olivares-Quintero J. Felix, East Michael P., Tanioka Maki, Zawistowski Jon S., Singh Darshan, Sciaky Noah, Chen Xin, He Xiaping, Rashid Naim U., Chollet-Hinton Lynn, Fan Cheng, Soloway Matthew G., Spears Patricia A., Jefferys Stuart, Parker Joel S., Gallagher Kristalyn K., Forero-Torres Andres, Krop Ian E., Thompson Alastair M., Murthy Rashmi, Gatza Michael L., Perou Charles M., Earp H. Shelton, Carey Lisa A., Johnson Gary L., FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036, npj Breast Cancer, 7, 1, 2021. Crossref

  153. Pierpaoli Elisa, Piacenza Francesco, Fiorillo Gaetano, Lombardi Paolo, Orlando Fiorenza, Salvatore Carmela, Geroni Cristina, Provinciali Mauro, Antimetastatic and Antitumor Activities of Orally Administered NAX014 Compound in a Murine Model of HER2-Positive Breast Cancer, International Journal of Molecular Sciences, 22, 5, 2021. Crossref

  154. Yamazaki Chisato M., Yamaguchi Aiko, Anami Yasuaki, Xiong Wei, Otani Yoshihiro, Lee Jangsoon, Ueno Naoto T., Zhang Ningyan, An Zhiqiang, Tsuchikama Kyoji, Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance, Nature Communications, 12, 1, 2021. Crossref

  155. Luo Liyun, Zhang Zhijie, Qiu Ni, Ling Li, Jia Xiaoting, Song Ying, Li Hongsheng, Li Jiansheng, Lyu Hui, Liu Hao, He Zhimin, Liu Bolin, Zheng Guopei, Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer, Nature Communications, 12, 1, 2021. Crossref

  156. Paricharak Shardul, Klenka Tom, Augustin Martin, Patel Umesh A, Bender Andreas, Are phylogenetic trees suitable for chemogenomics analyses of bioactivity data sets: the importance of shared active compounds and choosing a suitable data embedding method, as exemplified on Kinases, Journal of Cheminformatics, 5, 1, 2013. Crossref

  157. Schwab Carlton L, Santin Alessandro D, Targeted therapy in the treatment of uterine serous carcinoma, Pharmacogenomics, 16, 2, 2015. Crossref

  158. Veeraraghavan Jamunarani, Gutierrez Carolina, Sethunath Vidyalakshmi, Mehravaran Sepideh, Giuliano Mario, Shea Martin J., Mitchell Tamika, Wang Tao, Nanda Sarmistha, Pereira Resel, Davis Robert, Goutsouliak Kristina, Qin Lanfang, De Angelis Carmine, Diala Irmina, Lalani Alshad S., Nagi Chandandeep, Hilsenbeck Susan G., Rimawi Mothaffar F., Osborne C. Kent, Schiff Rachel, Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models, npj Breast Cancer, 7, 1, 2021. Crossref

  159. Fedorova Olga, Daks Alexandra, Shuvalov Oleg, Kizenko Alena, Petukhov Alexey, Gnennaya Yulia, Barlev Nikolai, Attenuation of p53 mutant as an approach for treatment Her2-positive cancer, Cell Death Discovery, 6, 1, 2020. Crossref

  160. Goyal Pankaj, Doval Dinesh Chandra, Agarwal Chaturbhuj, Jain Parveen, Chaudhari Krushna, Domadia Kshitij, Redhu Pallavi, Koyyala Venkata Pradeep Babu, Goel Varun, Batra Ullas, Talwar Vineet, Bothra Sneha, Current Treatment Approaches for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Adjuvant and Neoadjuvant Settings, Indian Journal of Medical and Paediatric Oncology, 42, 01, 2021. Crossref

  161. Chen Jesse S., Chen Jingwen, Bhattacharjee Somnath, Cao Zhengyi, Wang Han, Swanson Scott D., Zong Hong, Baker James R., Wang Su He, Functionalized nanoparticles with targeted antibody to enhance imaging of breast cancer in vivo, Journal of Nanobiotechnology, 18, 1, 2020. Crossref

  162. Yap Kah Min, Sekar Mahendran, Wu Yuan Seng, Gan Siew Hua, Rani Nur Najihah Izzati Mat, Seow Lay Jing, Subramaniyan Vetriselvan, Fuloria Neeraj Kumar, Fuloria Shivkanya, Lum Pei Teng, Hesperidin and its aglycone hesperetin in breast cancer therapy: A review of recent developments and future prospects, Saudi Journal of Biological Sciences, 28, 12, 2021. Crossref

  163. Li Bo, Yang Lili, Creatine in T Cell Antitumor Immunity and Cancer Immunotherapy, Nutrients, 13, 5, 2021. Crossref

  164. Pacheco-Velázquez Silvia Cecilia, Robledo-Cadena Diana Xochiquetzal, Hernández-Reséndiz Ileana, Gallardo-Pérez Juan Carlos, Moreno-Sánchez Rafael, Rodríguez-Enríquez Sara, Energy Metabolism Drugs Block Triple Negative Breast Metastatic Cancer Cell Phenotype, Molecular Pharmaceutics, 15, 6, 2018. Crossref

  165. Mazumder Aloran, Shiao Stephen, Haricharan Svasti, HER2 Activation and Endocrine Treatment Resistance in HER2-negative Breast Cancer, Endocrinology, 162, 10, 2021. Crossref

  166. Wijaya David Andi, Louisa Melva, Wibowo Heri, Taslim Aslim, Permata Tiara Bunga Mayang, Handoko Handoko, Nuryadi Endang, Kodrat Henry, Gondhowiardjo Soehartati Argadikoesoema, The future potential of Annona muricata L. extract and its bioactive compounds as radiation sensitizing agent: proposed mechanisms based on a systematic review, Journal of Herbmed Pharmacology, 10, 2, 2021. Crossref

  167. Li Wen-Qing, Wang Zhigang, Hao Sijie, He Hongzhang, Wan Yuan, Zhu Chuandong, Sun Li-Ping, Cheng Gong, Zheng Si-Yang, Mitochondria-Targeting Polydopamine Nanoparticles To Deliver Doxorubicin for Overcoming Drug Resistance, ACS Applied Materials & Interfaces, 9, 20, 2017. Crossref

  168. Chen Yongqiang, Wang Ruobing, Huang Shujun, Henson Elizabeth S., Bi Jayce, Gibson Spencer B., Erb-b2 Receptor Tyrosine Kinase 2 (ERBB2) Promotes ATG12-Dependent Autophagy Contributing to Treatment Resistance of Breast Cancer Cells, Cancers, 13, 5, 2021. Crossref

  169. Rimawi Mothaffar F., Schiff Rachel, Osborne C. Kent, Targeting HER2 for the Treatment of Breast Cancer, Annual Review of Medicine, 66, 1, 2015. Crossref

  170. de Paula Costa Monteiro Inês, Madureira Pedro, de Vasconscelos Alessandro, Humberto Pozza Daniel, Andrade de Mello Ramon, Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies, Pharmacogenomics, 16, 3, 2015. Crossref

  171. Liberelle Maxime, Jonckheere Nicolas, Melnyk Patricia, Van Seuningen Isabelle, Lebègue Nicolas, EGF-Containing Membrane-Bound Mucins: A Hidden ErbB2 Targeting Pathway?, Journal of Medicinal Chemistry, 63, 10, 2020. Crossref

  172. Narayanankutty Arunaksharan, Phytochemicals as PI3K/ Akt/ mTOR Inhibitors and Their Role in Breast Cancer Treatment, Recent Patents on Anti-Cancer Drug Discovery, 15, 3, 2020. Crossref

  173. Kiepas Alex, Voorand Elena, Senecal Julien, Ahn Ryuhjin, Annis Matthew G., Jacquet Kévin, Tali George, Bisson Nicolas, Ursini-Siegel Josie, Siegel Peter M., Brown Claire M., The SHCA adapter protein cooperates with lipoma-preferred partner in the regulation of adhesion dynamics and invadopodia formation, Journal of Biological Chemistry, 295, 31, 2020. Crossref

  174. Peake Bridgette F, Nahta Rita, Resistance to HER2-targeted therapies: a potential role for FOXM1, Breast Cancer Management, 3, 5, 2014. Crossref

  175. Yu De-Hua, Tang Lili, Dong Hua, Dong Zhengwei, Zhang Lianhai, Fu Jiangang, Su Xinying, Zhang Tianwei, Fu Haihua, Han Lu, Xie Liang, Chen Hao, Qian Ziliang, Zhu Guanshan, Wang Jia, Ye Qingqing, Zhang Jingchuan, Yin Xiaolu, Zhang Xiaolin, Ji Jiafu, Ji Qunsheng, Oncogenic HER2 fusions in gastric cancer, Journal of Translational Medicine, 13, 1, 2015. Crossref

  176. D'Huyvetter Matthias, De Vos Jens, Xavier Catarina, Pruszynski Marek, Sterckx Yann G.J., Massa Sam, Raes Geert, Caveliers Vicky, Zalutsky Michael R., Lahoutte Tony, Devoogdt Nick, 131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment, Clinical Cancer Research, 23, 21, 2017. Crossref

  177. Cordo Russo R I, Béguelin W, Díaz Flaqué M C, Proietti C J, Venturutti L, Galigniana N, Tkach M, Guzmán P, Roa J C, O'Brien N A, Charreau E H, Schillaci R, Elizalde P V, Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance, Oncogene, 34, 26, 2015. Crossref

  178. Mercogliano María F., De Martino Mara, Venturutti Leandro, Rivas Martín A., Proietti Cecilia J., Inurrigarro Gloria, Frahm Isabel, Allemand Daniel H., Deza Ernesto Gil, Ares Sandra, Gercovich Felipe G., Guzmán Pablo, Roa Juan C., Elizalde Patricia V., Schillaci Roxana, TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer, Clinical Cancer Research, 23, 3, 2017. Crossref

  179. Kang Minwoo, Shin Jong Il, Han Sangjin, Kim Jung Young, Park Jeonghoon, Kim Kwang Il, Kang Joo Hyun, Lee Tae Sup, Therapeutic Response Monitoring with 89Zr-DFO-Pertuzumab in HER2-Positive and Trastuzumab-Resistant Breast Cancer Models, Pharmaceutics, 14, 7, 2022. Crossref

  180. East Michael P., Johnson Gary L., Adaptive chromatin remodeling and transcriptional changes of the functional kinome in tumor cells in response to targeted kinase inhibition, Journal of Biological Chemistry, 298, 2, 2022. Crossref

  181. Turcotte Martin, Allard David, Mittal Deepak, Bareche Yacine, Buisseret Laurence, José Vinu, Pommey Sandra, Delisle Vincent, Loi Sherene, Joensuu Heikki, Kellokumpu-Lehtinen Pirkko-Liisa, Sotiriou Christos, Smyth Mark J., Stagg John, CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy, Cancer Research, 77, 20, 2017. Crossref

  182. Yoshida Taku, Kim Jee Hyun, Carver Kristopher, Su Ying, Weremowicz Stanislawa, Mulvey Laura, Yamamoto Shoji, Brennan Cameron, Mei Shenglin, Long Henry, Yao Jun, Polyak Kornelia, CLK2 Is an Oncogenic Kinase and Splicing Regulator in Breast Cancer, Cancer Research, 75, 7, 2015. Crossref

  183. Bartolacci Caterina, Andreani Cristina, Curcio Claudia, Occhipinti Sergio, Massaccesi Luca, Giovarelli Mirella, Galeazzi Roberta, Iezzi Manuela, Tilio Martina, Gambini Valentina, Wang Junbiao, Marchini Cristina, Amici Augusto, Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer, Cancer Immunology Research, 6, 12, 2018. Crossref

  184. Zhou Yubing, Han Chao, Li Duolu, Yu Zujiang, Li Fengmei, Li Feng, An Qi, Bai Huili, Zhang Xiaojian, Duan Zhenfeng, Kan Quancheng, Cyclin-dependent kinase 11p110 (CDK11p110) is crucial for human breast cancer cell proliferation and growth, Scientific Reports, 5, 1, 2015. Crossref

  185. Wadas Thaddeus J., Pandya Darpan N., Solingapuram Sai Kiran Kumar, Mintz Akiva, Molecular Targeted α-Particle Therapy for Oncologic Applications, American Journal of Roentgenology, 203, 2, 2014. Crossref

  186. Yousefi Hassan, Fong Jordyn, Alahari Suresh K., NR4A Family Genes: A Review of Comprehensive Prognostic and Gene Expression Profile Analysis in Breast Cancer, Frontiers in Oncology, 12, 2022. Crossref

  187. Wu Fei, Gardinier Thomas C., Turker Melik Z., Chen Feng, Chen Pei-Ming, Venkatesan Aranapakam M., Patel Vaibhav, Adams Gregory P., Bradbury Michelle S., Wiesner Ulrich B., Germano Geno, Ma Kai, Molecular Engineering of Surface Functional Groups Enabling Clinical Translation of Nanoparticle–Drug Conjugates, Chemistry of Materials, 34, 12, 2022. Crossref

  188. Knutson Keith L., Clynes Raphael, Shreeder Barath, Yeramian Patrick, Kemp Kathleen P., Ballman Karla, Tenner Kathleen S., Erskine Courtney L., Norton Nadine, Northfelt Donald, Tan Winston, Calfa Carmen, Pegram Mark, Mittendorf Elizabeth A., Perez Edith A., Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain, Cancer Research, 76, 13, 2016. Crossref

  189. Ring Alistair, Wheatley Duncan, Hatcher Helen, Laing Robert, Plummer Ruth, Uttenreuther-Fischer Martina, Temple Graham, Pelling Katy, Schnell David, Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer, Clinical Cancer Research, 21, 12, 2015. Crossref

  190. Schwill Martin, Tamaskovic Rastislav, Gajadhar Aaron S., Kast Florian, White Forest M., Plückthun Andreas, Systemic analysis of tyrosine kinase signaling reveals a common adaptive response program in a HER2-positive breast cancer, Science Signaling, 12, 565, 2019. Crossref

  191. Ngamcherdtrakul Worapol, Bejan Daniel S., Cruz‐Muñoz William, Reda Moataz, Zaidan Husam Y., Siriwon Natnaree, Marshall Suphalak, Wang Ruijie, Nelson Molly A., Rehwaldt Justin P. C., Gray Joe W., Hynynen Kullervo, Yantasee Wassana, Targeted Nanoparticle for Co‐delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2 + Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis , Small, 18, 11, 2022. Crossref

  192. Candas Demet, Lu Chung-Ling, Fan Ming, Chuang Frank Y.S., Sweeney Colleen, Borowsky Alexander D., Li Jian Jian, Mitochondrial MKP1 Is a Target for Therapy-Resistant HER2-Positive Breast Cancer Cells, Cancer Research, 74, 24, 2014. Crossref

  193. Meric-Bernstam Funda, Johnson Amber M., Dumbrava Ecaterina E. Ileana, Raghav Kanwal, Balaji Kavitha, Bhatt Michelle, Murthy Rashmi K., Rodon Jordi, Piha-Paul Sarina A., Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer, Clinical Cancer Research, 25, 7, 2019. Crossref

  194. Wiedermann Ursula, Garner-Spitzer Erika, Chao Yee, Maglakelidze Marina, Bulat Iurie, Dechaphunkul Arunee, Arpornwirat Wichit, Charoentum Chaiyut, Yen Chia-Jui, Yau Thomas Cheung, Tanasanvimon Suebpong, Maneechavakajorn Jedzada, Sookprasert Aumkhae, Bai Li-Yuan, Chou Wen-Chi, Ungtrakul Teerapat, Drinic Mirjana, Tobias Joshua, Zielinski Christoph C., Chong Leslie, Ede Nicholas J., Marino Mark T., Good Anthony J., Clinical and Immunologic Responses to a B-Cell Epitope Vaccine in Patients with HER2/neu-Overexpressing Advanced Gastric Cancer—Results from Phase Ib Trial IMU.ACS.001, Clinical Cancer Research, 27, 13, 2021. Crossref

  195. Wang Lei, Wang Quanren, Xu Piaopiao, Fu Li, Li Yun, Fu Haoyu, Quan Haitian, Lou Liguang, YES1 amplification confers trastuzumab–emtansine (T-DM1) resistance in HER2-positive cancer, British Journal of Cancer, 123, 6, 2020. Crossref

  196. Yan Y, Hein A L, Greer P M, Wang Z, Kolb R H, Batra S K, Cowan K H, A novel function of HER2/Neu in the activation of G2/M checkpoint in response to γ-irradiation, Oncogene, 34, 17, 2015. Crossref

  197. Rexer Brent N., Arteaga Carlos L., Optimal Targeting of HER2–PI3K Signaling in Breast Cancer: Mechanistic Insights and Clinical Implications, Cancer Research, 73, 13, 2013. Crossref

  198. Shinde Aparna, Kulkoyluoglu Cotul Eylem, Chen Hao, Smith Andrew, Libring Sarah, Solorio Luis, Wendt Michael K., Transglutaminase-2 mediates acquisition of neratinib resistance in metastatic breast cancer, Molecular Biomedicine, 3, 1, 2022. Crossref

  199. Console Lara, Scalise Mariafrancesca, Extracellular Vesicles and Cell Pathways Involved in Cancer Chemoresistance, Life, 12, 5, 2022. Crossref

  200. Menon Sreeja Raj, Mitra Arpit, Chakraborty Avik, Tawate Megha, Sahu Sudeep, Rakshit Sutapa, Gaikwad Sujay, Dhotre Geetanjali, Damle Archana, Banerjee Sharmila, Clinical Dose Preparation of [177Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [177Lu]LuCl3 for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers, with HER2 Receptor Overexpression, Cancer Biotherapy and Radiopharmaceuticals, 37, 5, 2022. Crossref

  201. Yuan Yang, Zhou Sensen, Li Cheng, Zhang Xiaoke, Mao Hui, Chen Weizhi, Jiang Xiqun, Cascade Downregulation of the HER Family by a Dual‐Targeted Recombinant Protein–Drug Conjugate to Inhibit Tumor Growth and Metastasis, Advanced Materials, 34, 23, 2022. Crossref

  202. Braig Zachary V., Personalized medicine: From diagnostic to adaptive, Biomedical Journal, 45, 1, 2022. Crossref

  203. Giuliano Mario, Hu Huizhong, Wang Yen-Chao, Fu Xiaoyong, Nardone Agostina, Herrera Sabrina, Mao Sufeng, Contreras Alejandro, Gutierrez Carolina, Wang Tao, Hilsenbeck Susan G., De Angelis Carmine, Wang Nicholas J., Heiser Laura M., Gray Joe W., Lopez-Tarruella Sara, Pavlick Anne C., Trivedi Meghana V., Chamness Gary C., Chang Jenny C., Osborne C. Kent, Rimawi Mothaffar F., Schiff Rachel, Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy, Clinical Cancer Research, 21, 17, 2015. Crossref

  204. Ouellette Michel M., Zhou Sumin, Yan Ying, Cell Signaling Pathways That Promote Radioresistance of Cancer Cells, Diagnostics, 12, 3, 2022. Crossref

  205. Boudjadi Salah, Pandey Puspa Raj, Chatterjee Bishwanath, Nguyen Thanh Hung, Sun Wenyue, Barr Frederic G., A Fusion Transcription Factor–Driven Cancer Progresses to a Fusion-Independent Relapse via Constitutive Activation of a Downstream Transcriptional Target, Cancer Research, 81, 11, 2021. Crossref

  206. Collins D C, Cocchiglia S, Tibbitts P, Solon G, Bane F T, McBryan J, Treumann A, Eustace A, Hennessy B, Hill A D, Young L S, Growth factor receptor/steroid receptor cross talk in trastuzumab-treated breast cancer, Oncogene, 34, 4, 2015. Crossref

  207. Castagnoli Lorenzo, Iezzi Manuela, Ghedini Gaia C., Ciravolo Valentina, Marzano Giulia, Lamolinara Alessia, Zappasodi Roberta, Gasparini Patrizia, Campiglio Manuela, Amici Augusto, Chiodoni Claudia, Palladini Arianna, Lollini Pier Luigi, Triulzi Tiziana, Menard Sylvie, Nanni Patrizia, Tagliabue Elda, Pupa Serenella M., Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab, Cancer Research, 74, 21, 2014. Crossref

  208. Shah Deep, Wyatt Debra, Baker Andrew T., Simms Patricia, Peiffer Daniel S., Fernandez Michelle, Rakha Emad, Green Andrew, Filipovic Alexandra, Miele Lucio, Osipo Clodia, Inhibition of HER2 Increases JAGGED1-dependent Breast Cancer Stem Cells: Role for Membrane JAGGED1, Clinical Cancer Research, 24, 18, 2018. Crossref

  209. Rimawi Mothaffar F., De Angelis Carmine, Schiff Rachel, Resistance to Anti-HER2 Therapies in Breast Cancer, American Society of Clinical Oncology Educational Book, 35, 2015. Crossref

  210. Oroujeni Maryam, Tano Hanna, Vorobyeva Anzhelika, Liu Yongsheng, Vorontsova Olga, Xu Tianqi, Westerlund Kristina, Orlova Anna, Tolmachev Vladimir, Karlström Amelie Eriksson, Affibody-Mediated PNA-Based Pretargeted Cotreatment Improves Survival of Trastuzumab-Treated Mice Bearing HER2-Expressing Xenografts, Journal of Nuclear Medicine, 63, 7, 2022. Crossref

  211. Rhodes Steven D., Angus Steven P., Prospects for Targeted Kinase Inhibition in Cancer: Neurofibromatosis Type 1-Related Neoplasia, in Comprehensive Pharmacology, 2022. Crossref

  212. Pareri Aanchal Udaynath, Koijam Arunkumar Singh, Kumar Chandan, Breaking the Silence of Tumor Response: Future Prospects of Targeted Radionuclide Therapy, Anti-Cancer Agents in Medicinal Chemistry, 22, 10, 2022. Crossref

  213. Pramanik Siddhartha Das, Kumar Halder Amit, Mukherjee Ushmita, Kumar Dharmendra, Dey Yadu Nandan, R Mogana, Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer, Frontiers in Chemistry, 10, 2022. Crossref

  214. Zhang Yuesheng, The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance, Pharmacology & Therapeutics, 218, 2021. Crossref

  215. Gámez-Chiachio Manuel, Sarrió David, Moreno-Bueno Gema, Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs, Cancers, 14, 18, 2022. Crossref

  216. Kumar Sandeep, Das Subhasis, Sun Jingjing, Huang Yixian, Singh Sunil Kumar, Srivastava Piush, Sondarva Gautam, Nair Rakesh Sathish, Viswakarma Navin, Ganesh Balaji B., Duan Lei, Maki Carl G., Hoskins Kent, Danciu Oana, Rana Basabi, Li Song, Rana Ajay, Mixed lineage kinase 3 and CD70 cooperation sensitize trastuzumab-resistant HER2 + breast cancer by ceramide-loaded nanoparticles , Proceedings of the National Academy of Sciences, 119, 38, 2022. Crossref

  217. Singh Desh Deepak, Lee Hae-Jeung, Yadav Dharmendra Kumar, Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer, Frontiers in Pharmacology, 13, 2022. Crossref

  218. Vivekanandhan Sneha, Knutson Keith L., Resistance to Trastuzumab, Cancers, 14, 20, 2022. Crossref

  219. Crocamo Susanne, Binato Renata, dos Santos Everton Cruz, de Paula Bruno, Abdelhay Eliana, Translational Results of Zo-NAnTax: A Phase II Trial of Neoadjuvant Zoledronic Acid in HER2-Positive Breast Cancer, International Journal of Molecular Sciences, 23, 24, 2022. Crossref

  220. Singh Navneet, Romick-Rosendale Lindsey, Watanabe-Chailland Miki, Privette Vinnedge Lisa M., Komurov Kakajan, Dey Nandini, Drug resistance mechanisms create targetable proteostatic vulnerabilities in Her2+ breast cancers, PLOS ONE, 17, 12, 2022. Crossref

Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections Prix et politiques d'abonnement Begell House Contactez-nous Language English 中文 Русский Português German French Spain